Advertisement

Update on management of genitourinary syndrome of menopause: A practical guide

      Abstract

      The term genitourinary syndrome of menopause (GSM) emerged following a consensus conference held in May 2013. GSM is a more descriptive term than vulvovaginal atrophy (VVA) and does not imply pathology. However there are concerns that GSM is all encompassing and includes not only symptoms resulting from estrogen deficiency, but also those arising from the effects of ageing and other processes on the bladder and pelvic floor.
      Focusing on symptoms related to estrogen deficiency, the update provides a practical guide for health and allied health professionals on the impact of GSM on women and their partners, assessment, management and areas for future research. As GSM is a chronic condition, long term therapy is required. Hormonal, nonhormonal, laser and alternative and complementary therapies are described.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Portman D.J.
        • Gass M.L.
        Vulvovaginal atrophy terminology consensus conference panel.
        in: MaturitasGenitourinary Syndrome of Menopause: New Terminology for Vulvovaginal Atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. 79. 2014: 349-354
        • Robinson D.
        • Giarenis I.
        • Cardozo L.
        New developments in the medical management of overactive bladder.
        Maturitas. 2013; 76: 225-229
        • Lüthje P.
        • Hirschberg A.L.
        • Brauner A.
        Estrogenic action on innate defense mechanisms in the urinary tract.
        Maturitas. 2013; 77: 32-36
        • Mody L.
        • Juthani-Mehta M.
        Urinary tract infections in older women: a clinical review.
        JAMA. 2014; 311: 844-854
        • Rees M.
        • Pérez-López F.R.
        • Ceausu I.
        • et al.
        EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.
        Maturitas. 2012; 73: 171-174
        • Raz R.
        Urinary tract infection in postmenopausal women.
        Korean J. Urol. 2011; 52: 801-808
        • Raz R.
        • Stamm W.E.
        A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
        N. Engl. J. Med. 1993; 329: 753-756
        • Calleja-Agius J.
        • Brincat M.
        Urogenital atrophy.
        Climacteric. 2009; 12: 279-285
        • Nappi R.E.
        • Palacios S.
        Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
        Climacteric. 2014; 17: 3-9
        • Parish S.J.
        • Nappi R.E.
        • Krychman M.L.
        • Kellogg-Spadt S.
        • Simon J.A.
        • Goldstein J.A.
        • Kingsberg S.A.
        Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy.
        Int. J. Womens Health. 2013; 5: 437-447
        • Nappi R.E.
        • Kokot-Kierepa M.
        Vaginal health insights, views & attitudes (VIVA) – results from an international survey.
        Climacteric. 2012; 15: 36-44
        • Levine K.B.
        • Williams R.E.
        • Hartmann K.E.
        Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.
        Menopause. 2008; 15: 661-666
        • Nappi R.E.
        • Kingsberg S.
        • Maamari R.
        • Simon J.
        The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.
        J. Sex. Med. 2013; 10: 2232-2241
        • Nappi R.E.
        • Mattsson L.Å.
        • Lachowsky M.
        • Maamari R.
        • Giraldi A.
        The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women andtheir partners in Northern and Southern Europe.
        Maturitas. 2013; 75: 373-379
        • Simon J.A.
        • Nappi R.E.
        • Kingsberg S.A.
        • Maamari R.
        • Brown V.
        Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners.
        Menopause. 2014; 21: 137-142
        • Kingsberg S.A.
        • Wysocki S.
        • Magnus L.
        • Krychman M.L.
        Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
        J. Sex. Med. 2013; 10: 1790-1799
        • Minkin M.J.
        • Reiter S.
        • Maamari R.
        Prevalence of postmenopausal symptoms in North America and Europe.
        Menopause. 2015; ([Epub ahead of print])https://doi.org/10.1097/GME
        • Castelo-Branco C.
        • Biglia N.
        • Nappi R.E.
        • Schwenkhagen A.
        • Palacios S.
        Characteristics of post-menopausal women with genitourinary syndrome of menopause: implications for vulvovaginal atrophy diagnosis and treatment selection.
        Maturitas. 2015; ([Epub ahead of print])https://doi.org/10.1016/j.maturitas.2015.05.007
        • Galhardo C.L.
        • Soares Jr., J.M.
        • Simões R.S.
        • Haidar M.A.
        • Rodrigues de Lima G.
        • Baracat E.C.
        Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy.
        Clin. Exp. Obstet. Gynecol. 2006; 33: 85-89
        • Wilson J.D.
        • Lee R.A.
        • Balen A.H.
        • Rutherford A.J.
        Bacterial vaginal flora in relation to changing oestrogen levels.
        Int. J. STD AIDS. 2007; 18: 308-311
        • Santen R.J.
        Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
        Climacteric. 2015; 18: 121-134
        • Suckling J.
        • Lethaby A.
        • Kennedy R.
        Local oestrogen for vaginal atrophy in postmenopausal women.
        Cochrane Database Syst. Rev. 2006; 18: CD001500
      1. Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, Ziegler KM, Aronson N. Menopausal Symptoms Comparative Effectiveness of Therapies. Comparative Effectiveness Review No. 147. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I.) AHRQ Publication No. 15-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2015. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

        • Simon J.
        • Nachtigall L.
        • Ulrich L.G.
        • Eugster-Hausmann M.
        • Gut R.
        Endometrial safety of ultra-low-dose estradiol vaginal tablets.
        Obstet. Gynecol. 2010; 116: 876-883
        • Notelovitz M.
        • Funk S.
        • Nanavati N.
        • Mazzeo M.
        Estradiol absorption from vaginal tablets in postmenopausal women.
        Obstet. Gynecol. 2002; 99: 556-562
      2. Ovestin 1mg cream. Summary of product characteristics. Last Updated on eMC 05-Nov-2014. https://www.medicines.org.uk/emc/medicine/28873 accessed 14.07.15.

      3. Vagifem 10 micrograms vaginal tablets. Summary of product characteristics. Last Updated on eMC 14-Jan-2015 https://www.medicines.org.uk/emc/medicine/23819/SPC/Vagifem+10+micrograms+vaginal+tablets accessed 14. 07.15.

        • Swanson S.G.
        • Drosman S.
        • Helmond F.A.
        • Stathopoulos V.M.
        Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study.
        Menopause. 2006; 13: 917-925
        • Mendoza N.
        • Abad P.
        • Baró F.
        • Cancelo M.J.
        • Llaneza P.
        • Manubens M.
        • Quereda F.
        • Sánchez-Borrego R.
        Spanish Menopause Society position statement: use of tibolone in postmenopausal women.
        Menopause. 2013; 20: 754-760
      4. Senshio. Summary of product characteristics http://ec.europa.eu/health/documents/community-register/2015/20150115130408/anx_130408_en.pdf accessed 14.07.15.

        • Wurz G.T.
        • Soe L.H.
        • DeGregorio M.W.
        Ospemifene, vulvovaginal atrophy, and breast cancer.
        Maturitas. 2013; 74: 220-225
        • Bachmann G.A.
        • Komi J.O.
        Ospemifene study group ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
        Menopause. 2010; 17: 480-486
        • Constantine G.D.
        • Goldstein S.R.
        • Archer D.F.
        Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
        Menopause. 2015; 22: 36-43
        • Portman D.
        • Palacios S.
        • Nappi R.E.
        • Mueck A.O.
        Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
        Maturitas. 2014; 78: 91-98
        • Simon J.
        • Portman D.
        • Mabey Jr, R.G.
        Ospemifene study group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
        Maturitas. 2014; 77: 274-281
        • Goldstein S.R.
        • Bachmann G.A.
        • Koninckx P.R.
        • Lin V.H.
        • Portman D.J.
        • Ylikorkala O.
        Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
        Climacteric. 2014; 17: 173-182
        • Portman D.J.
        • Bachmann G.A.
        • Simon J.A.
        Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
        Menopause. 2013; 20: 623-630
        • Simon J.A.
        • Lin V.H.
        • Radovich C.
        • Bachmann G.A.
        Ospemifene study group one-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
        Menopause. 2013; 20: 418-427
        • Gennari L.
        Lasofoxifene a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
        Expert Opin. Pharmacother. 2009; 10: 2209-2220
        • Panjari M.
        • Davis S.R.
        Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
        Maturitas. 2011; 70: 22-25
        • Labrie F.
        • Archer D.F.
        • Bouchard C.
        • Girard G.
        • Ayotte N.
        • Gallagher J.C.
        • Cusan L.
        • Baron M.
        • Blouin F.
        • Waldbaum A.S.
        • Koltun W.
        • Portman D.J.
        • Côté I.
        • Lavoie L.
        • Beauregard A.
        • Labrie C.
        • Martel C.
        • Balser J.
        • Moyneur E.
        • other participating Members of the VVA Prasterone Group
        Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
        Maturitas. 2015; 81: 46-56
        • Portman D.J.
        • Labrie F.
        • Archer D.F.
        • Bouchard C.
        • Cusan L.
        • Girard G.
        • Ayotte N.
        • Koltun W.
        • Blouin F.
        • Young D.
        • Wade A.
        • Martel C.
        • Dubé R.
        • other participating members of the VVA Prasterone Group
        Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
        Menopause. 2015; ([Epub ahead of print]): 470https://doi.org/10.1097/GME
      5. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902.

        • Rosen A.D.
        • Rosen T.
        Study of condom integrity after brief exposure to over-the-counter vaginal preparations.
        South Med. J. 1999; 92: 305-307
        • Juraskova I.
        • Jarvis S.
        • Mok K.
        • Peate M.
        • Meiser B.
        • Cheah B.C.
        • Mireskandari S.
        • Friedlander M.
        The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.
        J. Sex. Med. 2013; 10: 2549-2558
        • Jozkowski K.N.
        • Herbenick D.
        • Schick V.
        • Reece M.
        • Sanders S.A.
        • Fortenberry J.D.
        Women’s perceptions about lubricant use and vaginal wetness during sexual activities.
        J. Sex. Med. 2013; 10: 484-492
        • Bygdeman M.
        • Swahn M.L.
        Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.
        Maturitas. 1996; 23: 259-263
        • Abban G.
        • Yildirim N.B.
        • Jetten A.M.
        Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin d3.
        Eur. J. Histochem. 2008; 52: 107-114
        • Salvatore S.
        • Leone Roberti Maggiore U.
        • Athanasiou S.
        • Origoni M.
        • Candiani M.
        • Calligaro A.
        • Zerbinati N.
        Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study.
        Menopause. 2015; 22: 845-849
        • Zerbinati N.
        • Serati M.
        • Origoni M.
        • Candiani M.
        • Iannitti T.
        • Salvatore S.
        • Marotta F.
        • Calligaro A.
        Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment.
        Lasers Med. Sci. 2015; 30: 429-436
        • Perino A.
        • Calligaro A.
        • Forlani F.
        • Tiberio C.
        • Cucinella G.
        • Svelato A.
        • Saitta S.
        • Calagna G.
        Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.
        Maturitas. 2015; 80: 296-301
        • Gambacciani M.
        • Levancini M.
        Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause.
        Minerva Ginecol. 2015; 67: 97-102
        • Manonai J.
        • Songchitsomboon S.
        • Chanda K.
        • Hong J.H.
        • Komindr S.
        The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial.
        Maturitas. 2006; 54: 135-140
        • D'Anna R.
        • Cannata M.L.
        • Atteritano M.
        • Cancellieri F.
        • Corrado F.
        • Baviera G.
        • Triolo O.
        • Antico F.
        • Gaudio A.
        • Frisina N.
        • Bitto A.
        • Polito F.
        • Minutoli L.
        • Altavilla D.
        • Marini H.
        • Squadrito F.
        Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study.
        Menopause. 2007; 14: 648-655
        • Reed S.D.
        • Newton K.M.
        • LaCroix A.Z.
        • Grothaus L.C.
        • Grieco V.S.
        • Ehrlich K.
        Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
        Menopause. 2008; 15: 51-58
        • Bouchard C.
        Herbal alternatives as substitutes for hormone therapy in urogenital atrophy: scientific evidence is needed.
        Menopause. 2008; 15: 12-13
        • Hummelen R.
        • Macklaim J.M.
        • Bisanz J.E.
        • Hammond J.A.
        • McMillan A.
        • Vongsa R.
        • Koenig D.
        • Gloor G.B.
        • Reid G.
        Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness.
        PLoS One. 2011; 6: e26602
        • Buchholz S.
        • Mögele M.
        • Lintermans A.
        • Bellen G.
        • Prasauskas V.
        • Ortmann O.
        • Grob P.
        • Neven P.
        • Donders G.
        Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
        Climacteric. 2015; 18: 252-259